D
Dong-Ying Liu
Researcher at Sun Yat-sen University
Publications - 6
Citations - 184
Dong-Ying Liu is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Lung cancer & HBsAg. The author has an hindex of 6, co-authored 6 publications receiving 164 citations.
Papers
More filters
Journal ArticleDOI
Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet
TL;DR: It is implicate that circulating AMC and LMR are regarded as independent prognostic factors for PFS and OS in previously untreated metastatic NSCLC patients receiving platinum-based doublet.
Journal ArticleDOI
Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
TL;DR: Elevated neutrophil‐to‐lymphocyte ratio has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC) patients treated with first‐line EGFR tyrosine kinase inhibitors (TKIs) is not fully addressed.
Journal ArticleDOI
Increased lymphocyte to monocyte ratio is associated with better prognosis in patients with newly diagnosed metastatic nasopharyngeal carcinoma receiving chemotherapy
TL;DR: Pre-treatment ALC and LMR were demonstrated to be independent prognostic factors in patient with newly diagnosed metastatic NPC receiving chemotherapy, while AMC did not retained its prognostic significance in COX multivariate analysis.
Journal ArticleDOI
Hepatitis B Virus Infection Is Associated with Poor Prognosis in Patients with Advanced Non Small Cell Lung Cancer.
TL;DR: It is found that HBsAg-positive status was an independent prognostic factor for OS in patients with advanced NSCLC, and future prospective studies are required to confirm the findings.
Journal ArticleDOI
Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors
TL;DR: It is demonstrated that preemptive lamivudine significantly reduced the prevalence of HBV reactivation in HBsAg seropositive patients with metastatic NSCLC receiving systemic chemotherapy.